PHS 2024-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Required) | PA 24 248

Opportunity Information: Apply for PA 24 248

The PHS 2024-2 Omnibus Solicitation from the National Institutes of Health (NIH), Funding Opportunity Number PA 24-248, is a standing (parent) Notice of Funding Opportunity designed to support U.S. small businesses seeking Small Business Technology Transfer (STTR) funding under the R41 (Phase I) and R42 (Phase II) mechanisms. The central goal is to move biomedical and behavioral innovations forward by pairing a small business with a nonprofit research institution in a formal collaboration, where the work aligns with the research and development missions of participating NIH Institutes and Centers. Unlike some other parent solicitations, this specific version is explicitly for applications that require at least one clinical trial to be proposed as part of the project plan, meaning the science must involve clinical trial activity rather than being purely preclinical or non-human research.

In practical terms, this opportunity is meant for small businesses that already have a credible pathway into human studies and can propose a real clinical trial (for example, a first-in-human study, feasibility study, early-stage efficacy study, or other trial design appropriate to the stage of development). Because it is an omnibus solicitation, it is not limited to a single disease area or technology type. Instead, applicants are expected to select a topic area and justify fit with the program interests of one or more NIH components. The solicitation points applicants to the broader SBIR/STTR Program Descriptions and Research Topics for NIH, CDC, and FDA, which function as the menu of topic areas and priorities that NIH expects applicants to address. The key is that the proposed work must clearly map to an institute or center mission and to a topic area where NIH is seeking innovation from small businesses.

Eligibility is focused on United States small businesses. Foreign organizations are not eligible to apply, and non-U.S. components of U.S. organizations are also not eligible to apply. At the same time, the notice indicates that foreign components, as defined under the NIH Grants Policy Statement, may be allowed in certain cases, which generally means limited, well-justified portions of the work can occur outside the U.S. when there is a strong scientific or practical rationale and when NIH policy requirements are met. As with STTR generally, the model assumes a partnership structure between the small business and a research institution, with both parties contributing meaningfully to the research effort and with the project designed to advance a product or service toward commercialization while meeting public health needs.

The funding instrument is a grant, and the activity category reflects NIHs broad public health mission areas (including health, environment, and related social service domains as represented in the listing). Multiple CFDA numbers are associated with this parent announcement, reflecting that many NIH institutes and centers participate and that awards can fall under different NIH program authorities depending on the mission area and awarding component. The opportunity is categorized as discretionary, which is typical for NIH competitive research funding.

The announcement was created on July 3, 2024, and shows an original closing date of April 5, 2025. In NIH parent solicitations, that date commonly corresponds to an end point in the current solicitation cycle, while actual submission is typically tied to specific standard due dates across the year for the SBIR/STTR program, so applicants usually need to plan around NIHs recurring receipt dates and ensure they are using the correct application package and instructions tied to PA 24-248. The listing does not specify an award ceiling or number of expected awards, which is also common for omnibus solicitations where budgets and award counts vary by institute, topic, and appropriations, and where awards depend heavily on application quality and program fit.

Overall, PA 24-248 is best understood as a broad entry point for U.S. small businesses that want to propose an STTR project involving at least one clinical trial and that can demonstrate a strong partnership with a research institution, a clear rationale for human study involvement, and a tight alignment with the scientific priorities of a participating NIH institute or center.

• The National Institutes of Health in the education, environment, health, income security and social services sector is offering a public funding opportunity titled "PHS 2024-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Required)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.113, 93.172, 93.173, 93.213, 93.233, 93.242, 93.273, 93.286, 93.307, 93.361, 93.393, 93.394, 93.395, 93.837, 93.838, 93.839, 93.840, 93.865, 93.866, 93.867, 93.879.
• This funding opportunity was created on 2024-07-03.
• Applicants must submit their applications by 2025-04-05. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: Small businesses.

Apply for PA 24 248

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: